JP2021509900A5 - - Google Patents

Info

Publication number
JP2021509900A5
JP2021509900A5 JP2020537138A JP2020537138A JP2021509900A5 JP 2021509900 A5 JP2021509900 A5 JP 2021509900A5 JP 2020537138 A JP2020537138 A JP 2020537138A JP 2020537138 A JP2020537138 A JP 2020537138A JP 2021509900 A5 JP2021509900 A5 JP 2021509900A5
Authority
JP
Japan
Prior art keywords
glycero
biotin
insulin
dipalmitoyl
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020537138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021509900A (ja
JP7517691B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/012557 external-priority patent/WO2019136386A1/en
Publication of JP2021509900A publication Critical patent/JP2021509900A/ja
Publication of JP2021509900A5 publication Critical patent/JP2021509900A5/ja
Application granted granted Critical
Publication of JP7517691B2 publication Critical patent/JP7517691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020537138A 2018-01-05 2019-01-07 糖尿病を処置するための脂質ベースのナノ粒子を含む組成物 Active JP7517691B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614109P 2018-01-05 2018-01-05
US62/614,109 2018-01-05
PCT/US2019/012557 WO2019136386A1 (en) 2018-01-05 2019-01-07 Compositions comprising lipid-based nanoparticles for treating diabetes mellitus

Publications (3)

Publication Number Publication Date
JP2021509900A JP2021509900A (ja) 2021-04-08
JP2021509900A5 true JP2021509900A5 (https=) 2022-01-17
JP7517691B2 JP7517691B2 (ja) 2024-07-17

Family

ID=67143976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020537138A Active JP7517691B2 (ja) 2018-01-05 2019-01-07 糖尿病を処置するための脂質ベースのナノ粒子を含む組成物

Country Status (11)

Country Link
US (2) US20200375913A1 (https=)
EP (1) EP3735232A4 (https=)
JP (1) JP7517691B2 (https=)
KR (1) KR20200106912A (https=)
CN (1) CN111712236A (https=)
AU (2) AU2019205795A1 (https=)
BR (1) BR112020013460A2 (https=)
CA (1) CA3086771A1 (https=)
MX (1) MX2020007067A (https=)
SG (1) SG11202005920PA (https=)
WO (1) WO2019136386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP7306718B2 (ja) 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
CA3136665A1 (en) 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US9872890B2 (en) * 2003-03-19 2018-01-23 Paul C. Davidson Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
EP1610758A4 (en) 2003-03-19 2011-11-02 Harry Hebblewhite METHOD AND SYSTEM FOR DETERMINING INSULIN DOSAGE PLANES AND CARBOHYDRATE / INSULIN RELATIONSHIPS IN DIABETICS
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US20100129428A1 (en) 2005-05-23 2010-05-27 Sdg, Inc. Supra molecular construct for delivery of interferon to a mammal
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) * 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US20120035105A1 (en) * 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
JP5819949B2 (ja) * 2010-06-10 2015-11-24 ミダテック リミテッド ナノ粒子フィルム送達システム
CN103501821A (zh) * 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
EP3247363A4 (en) * 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
JP7306718B2 (ja) * 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子

Similar Documents

Publication Publication Date Title
JP2023120371A5 (https=)
JP2025085727A5 (https=)
US20220160841A1 (en) Glucose-responsive insulin delivery microneedle system
JP2021509900A5 (https=)
Saito et al. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery
KR101747433B1 (ko) 경구 생체이용가능한 지질-기재 구조물
JP2020510705A5 (https=)
KR20060014027A (ko) 지속성의 주사용 인슐린 조성물 및 그 제조방법 및사용방법
US20180271792A1 (en) Oral delivery of physiologically active substances
KR102849595B1 (ko) 안정성이 증진된 지질 기반 나노입자
ES2965028T3 (es) Producto liofilizado y suspensión de microvesículas llenas de gas
EP2680822B1 (en) Vesicle compositions
Sun et al. Development of functional or medical foods for oral administration of insulin for diabetes treatment: Gastroprotective edible microgels
US12161749B2 (en) Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery
Oguma et al. Effects of phospholipid type and particle size on lipid nanoparticle distribution in vivo and in pancreatic islets
JP2022526842A5 (https=)
JP7517691B2 (ja) 糖尿病を処置するための脂質ベースのナノ粒子を含む組成物
Tariq et al. Design, optimization & characterization of niosomal & polymeric nanoparticles
JP2020500203A (ja) サーファクタントタンパク質bと1つ以上の脂質とを含む粒子
Kunte et al. Evaluation of transfection efficacy, biodistribution, and toxicity of branched amphiphilic peptide capsules (BAPCs) associated with mRNA
JP2022526842A (ja) 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法
CN1631444A (zh) 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法
JP2009507761A5 (https=)
KR20200067173A (ko) 포도당-반응성 인슐린 전달을 위한 포도당 전달체 억제제-조절 인슐린
US9408917B2 (en) Pharmaceutical composition